Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
SAN DIEGO, Sept. 14, 2016 -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Alvin Shih, M.D., executive vice president and head of research & development, will present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series in New York City on Wednesday, September 28, 2016 at 11:05 a.m. ET.
A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and an archived replay will be accessible for up to 90 days.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Thiola®, Cholbam® and Chenodal®.
Contacts: (Investors) Chris Cline, CFA Senior Director, Investor Relations 646-564-3680 [email protected]
